Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-09-18
2007-09-18
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S399000
Reexamination Certificate
active
10477651
ABSTRACT:
The invention provides a growth hormone (GH) in which amino acids within the regulated secretory pathway (RSP) sorting signal have been mutated as well as a GH in which the three-dimensional conformation of the RSP sorting signal has been altered, and a composition comprising an effective amount of such a GH in an excipient.
REFERENCES:
patent: 4797368 (1989-01-01), Carter et al.
patent: 4816439 (1989-03-01), Jorgensen
patent: 5096885 (1992-03-01), Pearlman et al.
patent: 5426096 (1995-06-01), Sönksen et al.
patent: 5567677 (1996-10-01), Castensson et al.
patent: 5580723 (1996-12-01), Wells et al.
patent: 5587308 (1996-12-01), Carter et al.
patent: 5612315 (1997-03-01), Pikal et al.
patent: 5633352 (1997-05-01), Dalbøge et al.
patent: 5635604 (1997-06-01), Dalbøge et al.
patent: 5654010 (1997-08-01), Johnson et al.
patent: 5667808 (1997-09-01), Johnson et al.
patent: 5734024 (1998-03-01), Zaslavsky
patent: 5763394 (1998-06-01), O'Connor et al.
patent: 5851992 (1998-12-01), Sørensen
patent: 5885971 (1999-03-01), German et al.
patent: 5891478 (1999-04-01), Johnson et al.
patent: 5898030 (1999-04-01), Samaritani
patent: 5981485 (1999-11-01), O'Connor et al.
patent: 6010999 (2000-01-01), Daley et al.
patent: 6013773 (2000-01-01), Kobayashi et al.
patent: 6022711 (2000-02-01), Cunningham et al.
patent: 6051259 (2000-04-01), Johnson et al.
patent: WO95/32991 (1995-12-01), None
patent: WO96/40072 (1996-12-01), None
patent: WO98/11244 (1998-03-01), None
patent: WO98/13511 (1998-04-01), None
patent: WO98/22143 (1998-05-01), None
patent: WO98/46778 (1998-10-01), None
patent: WO99/61601 (1999-12-01), None
patent: WO 00/17376 (2000-03-01), None
patent: WO 00/40741 (2000-07-01), None
Baccaglini et al., “Cationic Liposome-mediated Gene Transfer to Rat Salivary Epithelial Cells in vitro and in vivo,”J. Gene. Med.vol. 3, pp. 82-90 (2001).
Baum et al., “Re-engineering the Functions of a Terminally Differentiated Epithelial Cell in Vivo,”Ann N.Y. Acad. Sci.,vol. 875, pp. 294-300 (1999).
Becker et al., “Use of Recombinant Adenovirus for Metabolic Engineering of Mammalian Cells,”Methods Cell Biol.,vol. 43 (Pt A), pp. 161-189 (1994).
Carroll et al., “Growth Hormone Replacement in Adults with Growth Hormone Deficiency: Assessment of Current Knowledge,”Trends Endocrinol. Metab.,vol. 11 (6), pp. 231-238 (2000).
Carter et al., “Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors,”Nucleic Acids Res.,vol. 13 (12), pp. 4431-4443 (1985).
Cool et al., “Identification of the Sorting Signal Motif within Pro-opiomelanocortin for the Regulated Secretory Pathway,”J. Biol. Chem.,vol. 270 (15), pp. 8723-8729 (1995).
D'Costa et al., “Human Immunodeficiency Virus Type 2 Lentiviral Vectors: Packaging Signal and Splice Donor in Expression and Encapsidation,”J. Gen. Virol.,vol. 82 (Pt 2), pp. 425-434 (2001).
Delporte et al., “Adenovirus-mediated Expression of Aquaporin-5 in Epithelial Cells,”J. Biol. Chem.,vol. 271 (36), pp. 22070-22075 (1996).
Finidori, “Regulators of Growth Hormone Signaling,”Vitam. Horm.,vol. 59, pp. 71-97 (2000).
Fisher et al., “A Novel Adenovirus-Adeno-Associated Virus Hybrid Vector that Displays Efficient Rescue and Delivery of the AAV Genome,”Hum. Gene Ther.,vol. 7, pp. 2079-2087 (1996).
Gorr et al., “Disruption of Disulfide Bonds Exhibits Differential Effects on Trafficking of Regulated Secretory Proteins,”Am. J. Physiol.,vol. 277, pp. C121-C131 (1999).
He et al., “Systemic Action of Human Growth Hormone Following Adenovirus-Mediated Gene Transfer to Rat Submandibular Glands,”Gene Ther.,vol. 5, pp. 537-541 (1998).
Lewis et al., “Structure and Properties of Members of the hGH Family: A Review,”Endocr. J.,vol. 47 (Suppl.), pp. S1-S8 (2000).
Liang et al., “Insulin Receptor Substrate-1 Enhances Growth Hormone-Induced Proliferation,”Endocrinology, vol. 140 (5), pp. 1972-1983 (1999).
Macgillivray et al., “Outcome of a Four-Year Randomized Study of Daily Versus Three Times Weekly Somatropin Treatment in Prepubertal Naive Growth Hormone-Deficient Children,”J. Clin. Endocrinol. Metab.,vol. 81 (5), pp. 1806-1809 (1996).
Mastrangeli et al., “Direct in vivo Adenovirus-Mediated Gene Transfer to Salivary Glands,”Am. J. Physiol.,vol. 266, pp. G1146-G1155 (1994).
Mehls et al., “Effects of Recombinant Human Growth Hormone in Catabolic Adults with Chronic Renal Failure,”Growth Horm. IGF Res.,vol. 10 (Suppl. B), pp. S31-S37 (2000).
Murray et al., “Growth Hormone: Current and Future Therapeutic Applications,”Exp. Opin. Pharmacotherapy, vol. 1 (5), pp. 975-990 (2000).
O'Connell et al., “Safety and Efficacy of Adenovirus-Mediated Transfer of the Human Aquaporin-1 cDNA to irradiated parotid glands of non-human primates,”Cancer Gene Ther.,vol. 6 (6), pp. 505-513 (1999).
Parkhurst et al., “Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues,”J. Immunol.,vol. 157, pp. 2539-2548 (1996).
Wang et al., “Adenoviral-mediated Gene Transfer to Mouse Salivary Glands,”J. Dent. Res.,vol. 79 (2), pp. 701-708 (2000).
Wells et al., “Cassette Mutagenesis: An Efficient Method for Generation of Multiple Mutations at Defined Sites,”Gene, vol. 34, pp. 315-323 (1985).
Wells et al., “Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin,”Phil. Trans. R. Soc. Lond.,vol. 317, p. 415-423 (1986).
Wit, “The Use of GH as Pharmacological Agent (minireview),”Endocr. Regul.,vol. 33 (1), pp. 28-32 (2000).
Zheng et al., “Genomic Integration and Gene Expression by a Modified Adenoviral Vector,”Nat. Biotechnol.,vol. 18, pp. 176-180 (2000).
Zoller et al., “Oligonucleotide-Directed Mutagenesis Using M13-Derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA,”Nucleic Acids Res.,vol. 10 (20), pp. 6487-6500 (1982).
Cool et al.,Cell, vol. 88, 73-83 (Jan. 10, 1997).
Zhang et al.,Mol. Endo.,13(4), 527-536 (1999).
Baum Bruce J.
Cawley Niamh
Loh Yoke Peng
Snell Christopher R.
Leydig , Voit & Mayer, Ltd.
Saoud Christine J.
United States of America, Represented by the Secretary, Departme
LandOfFree
Modified growth hormone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified growth hormone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified growth hormone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3776117